JP2021509916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509916A5 JP2021509916A5 JP2020557135A JP2020557135A JP2021509916A5 JP 2021509916 A5 JP2021509916 A5 JP 2021509916A5 JP 2020557135 A JP2020557135 A JP 2020557135A JP 2020557135 A JP2020557135 A JP 2020557135A JP 2021509916 A5 JP2021509916 A5 JP 2021509916A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- effective
- composition according
- pic1 peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 101100153168 Arabidopsis thaliana TIC21 gene Proteins 0.000 claims 10
- 101100273813 Homo sapiens CDKN1A gene Proteins 0.000 claims 10
- 108700038981 SUMO-1 Proteins 0.000 claims 10
- 101100083337 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pic1 gene Proteins 0.000 claims 10
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 230000015572 biosynthetic process Effects 0.000 claims 6
- 210000004072 lung Anatomy 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 239000010836 blood and blood product Substances 0.000 claims 2
- 229940125691 blood product Drugs 0.000 claims 2
- 230000004154 complement system Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 208000037816 tissue injury Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025426A JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615183P | 2018-01-09 | 2018-01-09 | |
| US62/615,183 | 2018-01-09 | ||
| US201862681458P | 2018-06-06 | 2018-06-06 | |
| US62/681,458 | 2018-06-06 | ||
| US201862746649P | 2018-10-17 | 2018-10-17 | |
| US62/746,649 | 2018-10-17 | ||
| PCT/US2019/012659 WO2019139886A1 (en) | 2018-01-09 | 2019-01-08 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025426A Division JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509916A JP2021509916A (ja) | 2021-04-08 |
| JP2021509916A5 true JP2021509916A5 (enExample) | 2021-07-26 |
| JP7031011B2 JP7031011B2 (ja) | 2022-03-07 |
Family
ID=67140101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557135A Active JP7031011B2 (ja) | 2018-01-09 | 2019-01-08 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
| JP2022025426A Active JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025426A Active JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US11135272B2 (enExample) |
| EP (2) | EP3740074B1 (enExample) |
| JP (2) | JP7031011B2 (enExample) |
| KR (2) | KR102420552B1 (enExample) |
| CN (1) | CN112512548A (enExample) |
| AU (2) | AU2019207508B2 (enExample) |
| CA (1) | CA3086407A1 (enExample) |
| ES (1) | ES2996888T3 (enExample) |
| IL (2) | IL287308B2 (enExample) |
| MX (3) | MX2020007098A (enExample) |
| SG (1) | SG11202006063RA (enExample) |
| WO (1) | WO2019139886A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| EP3740074B1 (en) | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
| AU2021355358A1 (en) * | 2020-09-30 | 2023-06-08 | Realta Life Sciences, Inc. | Peptides and methods of use |
| JP2023548343A (ja) * | 2020-11-02 | 2023-11-16 | レアルタ ライフ サイエンシズ インコーポレイテッド | ペプチドおよび使用方法 |
| CN116528886A (zh) * | 2020-11-02 | 2023-08-01 | 瑞尔塔生命科学公司 | 肽及其使用方法 |
| IL302567A (en) * | 2020-11-09 | 2023-07-01 | Realta Life Sciences Inc | Peptide formulations and methods of use |
| IL308683A (en) * | 2021-06-01 | 2024-01-01 | Realta Life Sciences Inc | Peptides and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| AU2729400A (en) | 1999-01-19 | 2000-08-07 | James Daly | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| KR101132287B1 (ko) | 2003-09-05 | 2012-04-05 | 도레이 도넨 기노마쿠 고도가이샤 | 열가소성 수지 미다공막의 제조 방법 |
| WO2005023296A1 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of rheumatic diseases |
| US7638481B2 (en) | 2003-09-05 | 2009-12-29 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2655371C (en) | 2006-06-15 | 2017-06-20 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| AU2008239595A1 (en) | 2007-04-11 | 2008-10-23 | Pestka Biomedical Laboratories, Inc. | Interferons of Rhesus and Cynomolgus origin and uses thereof |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US20130183662A1 (en) * | 2010-04-22 | 2013-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| PL3178841T3 (pl) * | 2010-07-21 | 2018-12-31 | Eastern Virginia Medical School | Związki peptydowe do regulowania układu dopełniacza |
| US10005818B2 (en) * | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| JP2015512369A (ja) | 2012-03-16 | 2015-04-27 | ベルローズ ファーマ，インコーポレーテッド | Ｃ１阻害剤のポリマーコンジュゲート |
| JP6820917B2 (ja) | 2015-06-26 | 2021-01-27 | レアルタ ホールディングス リミテッド ライアビリティ カンパニー | 合成ペプチド化合物及び使用方法 |
| EP3740074B1 (en) | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
-
2019
- 2019-01-08 EP EP19738307.8A patent/EP3740074B1/en active Active
- 2019-01-08 MX MX2020007098A patent/MX2020007098A/es unknown
- 2019-01-08 CN CN201980007577.6A patent/CN112512548A/zh active Pending
- 2019-01-08 US US16/242,550 patent/US11135272B2/en active Active
- 2019-01-08 CA CA3086407A patent/CA3086407A1/en active Pending
- 2019-01-08 KR KR1020207022678A patent/KR102420552B1/ko active Active
- 2019-01-08 ES ES19738307T patent/ES2996888T3/es active Active
- 2019-01-08 WO PCT/US2019/012659 patent/WO2019139886A1/en not_active Ceased
- 2019-01-08 EP EP24203120.1A patent/EP4464716A3/en active Pending
- 2019-01-08 AU AU2019207508A patent/AU2019207508B2/en active Active
- 2019-01-08 KR KR1020227023661A patent/KR20220104268A/ko not_active Ceased
- 2019-01-08 IL IL287308A patent/IL287308B2/en unknown
- 2019-01-08 JP JP2020557135A patent/JP7031011B2/ja active Active
- 2019-01-08 SG SG11202006063RA patent/SG11202006063RA/en unknown
-
2020
- 2020-04-03 US US16/839,464 patent/US11020460B2/en active Active
- 2020-07-06 IL IL275867A patent/IL275867B/en unknown
- 2020-07-13 MX MX2025009095A patent/MX2025009095A/es unknown
- 2020-07-13 MX MX2025009081A patent/MX2025009081A/es unknown
-
2021
- 2021-04-30 US US17/245,213 patent/US11712462B2/en active Active
-
2022
- 2022-02-22 JP JP2022025426A patent/JP7341268B2/ja active Active
-
2023
- 2023-06-09 US US18/332,026 patent/US12257290B2/en active Active
-
2024
- 2024-07-31 AU AU2024205230A patent/AU2024205230A1/en active Pending
-
2025
- 2025-02-19 US US19/057,376 patent/US20250177492A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509916A5 (enExample) | ||
| Zehender et al. | Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up | |
| EP0585705B1 (en) | Use of monoclonal antibodies to TNF to treat bacterial meningitis | |
| Nguyen et al. | Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer | |
| Salvin et al. | Brief communication: tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity | |
| JP2016516016A5 (enExample) | ||
| JP2011528333A5 (enExample) | ||
| Nishimura et al. | Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2 | |
| Mirbahari et al. | Recent progress in combination therapy of oncolytic vaccinia virus | |
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| US8877203B2 (en) | Composition and method for preventing and treating immune-related disorder | |
| JP2015514756A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| Lam et al. | Targeting mesenchymal stem cell therapy for severe pneumonia patients | |
| JP2019501925A5 (enExample) | ||
| IL291574B2 (en) | Methods for using 5-Adenosine Diphosphate Ribose (ADPR) | |
| JP2017508455A5 (enExample) | ||
| WO2016071431A9 (en) | A combination for cancer therapy | |
| CN115282280A (zh) | TGF-β1信号抑制剂的新用途 | |
| JP2018529747A5 (enExample) | ||
| US7846901B2 (en) | Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P | |
| KR20210022577A (ko) | 종양 진행 제어용 또는 항 종양 면역 회복용 대식 세포 및 조사된 백혈구의 공동 배양으로부터의 상청액 | |
| Morales et al. | Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers | |
| CN102309502B (zh) | CpG-ODN2395在制备治疗辐射损伤药物中的应用 | |
| Cheng et al. | Nobiletin protects against monocrotaline-induced pulmonary arterial hypertension in rats by regulating Src/STAT3 signaling pathway |